期刊
LUNG CANCER MANAGEMENT
卷 5, 期 2, 页码 91-104出版社
FUTURE MEDICINE LTD
DOI: 10.2217/lmt-2016-0006
关键词
CTCs; ctDNA; early detection; exosomes; liquid biopsy; minimal residual disease; NSCLC; personalized medicine; resistance monitoring; therapy options; tumor burden; tumor evolution
资金
- AIRC/MGAF [12983]
In the era of high-throughput molecular screening and personalized medicine, difficulty in determining whether cancer mutations are truly 'actionable' remains a gray zone in NSCLC. The most important prerequisite to perform such investigations is the tumor tissue retrieval via biopsy at diagnosis and after occurrence of resistance. Blood-based liquid biopsy as circulating tumor cells, circulating tumor DNA and exosomes can offer a fast and non-invasive method to elucidate the genetic heterogeneity of patients, the screening and patient stratification and give a dynamic surveillance for tumor progression and monitor treatments response. Here we prospectively discuss the three main approaches in the blood-biopsy field of lung cancer patients and its clinical applications in patient management. We also outline some of the analytical challenges that remain for liquid biopsy techniques in demonstrating that it could represent a true and actionable picture in lung cancer management for the implementation into clinical routine.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据